Share Name Share Symbol Market Type Share ISIN Share Description
Iq-ai Limited LSE:IQAI London Ordinary Share JE00BD4H0R42 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -4.76% 10.00 10,224,714 16:35:13
Bid Price Offer Price High Price Low Price Open Price
9.70 10.00 10.75 9.64 10.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 0.27 -0.62 -0.50 16
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:07 O 2,416,667 9.75 GBX

Iq-ai (IQAI) Latest News (1)

More Iq-ai News
Iq-ai Investors    Iq-ai Takeover Rumours

Iq-ai (IQAI) Discussions and Chat

Iq-ai Forums and Chat

Date Time Title Posts
04/12/202020:03Imaging Quantification - Artificial Intelligence6,057

Add a New Thread

Iq-ai (IQAI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Iq-ai trades in real-time

Iq-ai (IQAI) Top Chat Posts

Iq-ai Daily Update: Iq-ai Limited is listed in the General Retailers sector of the London Stock Exchange with ticker IQAI. The last closing price for Iq-ai was 10.50p.
Iq-ai Limited has a 4 week average price of 9.60p and a 12 week average price of 4.30p.
The 1 year high share price is 22.75p while the 1 year low share price is currently 1.95p.
There are currently 160,522,649 shares in issue and the average daily traded volume is 4,178,008 shares. The market capitalisation of Iq-ai Limited is Ā£16,052,264.90.
iambix: I don't think that Trevor Brown and the other directors intend to sell any of their shares. The reason being that their holdings are so large that the share price would crash if they did, and they would all be acting against themselves. Their plan will be to see if IQAI's products sell well over the next year. If this happens, they intend to put the company up for sale and get a much better price for their shareholdings. They control nearly half the company, so it would be easy for them to sell it. I think the share price will remain at about 10p for several months now, until next Summer when we learn the sales figures. I expect that the directors plan for IQAI to be sold off within the next three years.
master rsi: Hollywood6 re - What monies do Iqai have for acquisition? A merger? You do not need money for that, just get a high enough share price Tomorrow could be the start of such a thing
leadersoffice: Don't you just love Tesla lol. What's best about it is not just the cars but it's knowing that all those sad shorters got so burnt trying to undermine the companies share price. How do you think it will fare in the S&P 500? Some analysts think the share price could be volatile either way. Just invested in Nio. They've just had a brokers upgrade and potentially the next Tesla.
master rsi: IQAI RESUME - Starting point to go ballistic 04 November 2020 - LSN Software Receives FDA Clearance IQ-AI today announces that the US Food and Drug Administration ("FDA") has granted 510(k) market clearance for the Liver Surface Nodularity ("LSN") software application. Earlier this year, IQ-AI's subsidiary, Imaging Biometrics, LLC ("IB"), entered into a business agreement with the owners of LSN, AI Metrics, LLC, which granted IB global rights to manufacture, market, and distribute the LSN software platform. Now that the FDA has granted market clearance, IB and AI Metrics will begin to actively market and sell LSN in the USA. CE mark for European distribution and commercialisation is expected later this quarter. LSN presents a new way to use CT scans for virtual liver biopsy to help assess individuals with chronic liver disease ("CLD"). CLD is a serious condition that progresses through various stages including liver inflammation, early fibrosis, advanced fibrosis, and cirrhosis. In total, over 2 billion people worldwide have some form of CLD which requires frequent monitoring for proper staging and treatment. Currently, the best way to monitor liver deterioration due to CLD is by undergoing a liver biopsy. The problem with liver biopsies is that they can be quite painful to the patient and expensive. A single liver biopsy can cost between $2,000 and $3,000 per test and is associated with a risk of bleeding. Biopsy sampling is also prone to errors which may result in misdiagnosis. LSN's proprietary algorithms process CT images of a patient's liver to assess the nodules along the liver surface. This low cost, low-risk, non-invasive procedure provides physicians with new information that may aid in the staging of CLD and has the potential to become the standard of care for a significant global market. -------------- 09 November 2020 / Q-AI Limited (IQAI.L) IB and the Mayo Clinic enter into an Agreement Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI, Ltd, has entered into an agreement (the “Agreement”) with Mayo Clinic to develop a brain lesion tracking platform, IB Trax. The collaboration’s objective is the development of an innovative AI technology to track metastatic and primary brain tumours. IB’s proven quantitative technologies will form the foundation of IB Trax and the overall workflow will receive direct clinical input from the Mayo Clinic. This Agreement considerably expands the existing relationship between IB and the Mayo Clinic by appointing Dr. Leland Hu, MD, an Assistant Professor of Radiology at the Mayo Clinic Arizona, to IB’s Scientific Advisory Board. Under the terms of the Agreement, IQ-AI will issue Mayo Clinic a token of $50,000 of shares in IQ-AI at a price equivalent to the three-month average share price prior to the effective date of the Agreement. In addition, IQ-AI will issue the Mayo Clinic, $10,000 of shares in IQ-AI at a price equivalent to the three-month average share price prior to the date the shares are issued, on the first anniversary and every successive year whilst the agreement is in existence. In addition, the Mayo Clinic will receive a 4% on-going royalty on each sale of IB Trax, including $20,000 on the initial commercial installation. Ultimately, the aim is to leverage IB’s existing quantitative solutions and AI expertise to develop a streamlined workflow that systematically identifies, tracks, and reports changes to brain lesions. Currently, the way clinicians perform this task is cumbersome and subjective. The Mayo Clinic is ideally positioned to assist in this effort as it is renowned for excellence and commonly treats the most challenging of brain tumour cases from around the world. “We are excited to team up with the Mayo Clinic to significantly expand the diagnostic utility of our core applications. This collaboration provides key clinical input to further enhance the design and guide development of IB Trax,” said Michael Schmainda, CEO of IB. Trevor Brown CEO of IQAI, commented, “IB have now entered a period of exponential growth in their development of innovative medical AI technologies.” ABOUT Imaging Biometrics , LLC Imaging BiometricsĀ®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company’s website at .
investmentguru: Takeover price has to be not less than the maximum price paid by the acquirer to buy their existing holding, offer price is not related to the share price.
billthebank: I know the bleedin answer!!! The MMs know I spread my risk between two stocks and tbey simply mirrored the share price performance so I wouldnt trade them. Watch IQAI and GDR fly this after!!!! Hah hah hah!!!
iambix: The share price has gone down today for two reasons (1) normal profit taking - especially when you look at Remote Monitored Systems and, more pertinently (2) frantic selling of everything showing a profit to put it into the stocks which have been bombed out by coronavirus and are dirt cheap. The new Pfizer vaccine of today means it's been a marvellous opportunity today to buy hotels, airlines and travel agencies. Shares in IQAI have been sold to buy these.
billthebank: Disappointing to see the share price retract to 17p but medium term IQAI looks like a cracker.Hope we have a positive few weeks!!! And of course an interesting day today.Come on lets get this back into the 20s!!!!
bmwman3: Trevor Brown(including shares held by Free Association Books) 43,419,766 29.75%Kathleen Schmainda* 9,108,400 6.24%West Coast Capital Investments 7,559,934 5.18%David Smith - started a company with £0. No staff. No office. Angel investors game him £22 million. The company went on to sale for £180 million. He thinks what they have here is much bigger. The MMs will try to take your shares cheap knowing this is worth much more. When they drop a share this hard, its because they want your shares. This company is going places, a small Market cap. I am being honest here. FDA took 2 years. When they drop the share price, i am loading up. This in a few months will be much much more than it is now. MMs have to do what they have to do to get shares. Don't be a victim. Do your research and stay in for the fundamentals. At EUA, the MMs dropped the share price hard to 16p. Where is it now? Tomorrow, more tree shake and i am a buyer.
bmwman3: I think we are in play now to be bought out, with approvals and software products validated and now being sold to mainstream hospitals someone will buy us but not for a small amount! IB/IQAI is undercapitalised to really push products to market quickly but GE can as an example. TB happy with rapid increase in share price which makes us more expensive to buy, a lot more to come over the months, could get north of 50p !
Iq-ai share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201204 20:54:56